Semler Scientific, Inc. (NASDAQ:SMLR – Get Free Report) was the target of unusually large options trading on Tuesday. Stock traders acquired 6,648 call options on the company. This represents an increase of approximately 289% compared to the typical daily volume of 1,709 call options.
Wall Street Analyst Weigh In
Separately, Wall Street Zen lowered Semler Scientific from a “buy” rating to a “sell” rating in a research report on Thursday, May 22nd.
Get Our Latest Stock Report on SMLR
Semler Scientific Stock Up 0.7%
Semler Scientific (NASDAQ:SMLR – Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.76) earnings per share for the quarter. The firm had revenue of $8.84 million during the quarter. Semler Scientific had a return on equity of 50.77% and a net margin of 72.65%.
Hedge Funds Weigh In On Semler Scientific
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Interchange Capital Partners LLC purchased a new stake in shares of Semler Scientific in the 1st quarter valued at approximately $46,502,000. Capital International Investors acquired a new stake in shares of Semler Scientific in the fourth quarter valued at $30,813,000. Susquehanna Advisors Group Inc. acquired a new stake in Semler Scientific in the 4th quarter valued at about $26,928,000. Driehaus Capital Management LLC acquired a new position in Semler Scientific during the 4th quarter worth approximately $10,122,000. Finally, Thames Capital Management LLC purchased a new position in Semler Scientific in the fourth quarter valued at $6,465,000. 49.37% of the stock is currently owned by institutional investors and hedge funds.
Semler Scientific Company Profile
Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.
Recommended Stories
- Five stocks we like better than Semler Scientific
- What Does Downgrade Mean in Investing?
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- What is a buyback in stocks? A comprehensive guide for investors
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- The Significance of Brokerage Rankings in Stock Selection
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.